Étiquette : randomization

The effects of psilocybin on cognitive and emotional functions in healthy participants : Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation, James J Rucker et al., 2021

The effects of psilocybin on cognitive and emotional functions in healthy participants : Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation James J Rucker, Lindsey Marwood, Riikka-Liisa J Ajantaival, Catherine Bird, Hans Eriksson, John Harrison, Molly Lennard-Jones, Sunil Mistry, Francesco Saldarini, Susan Stansfield, Sara J Tai, Sam Williams, Neil Weston, Ekaterina Malievskaia and Allan H Young     Abstract Background : Psilocybin, a psychoactive serotonin receptor partial agonist, has been reported to acutely reduce clinical symptoms of depressive disorders. Psilocybin’s effects on cognitive function have not been widely or systematically studied. Aim : The aim of this study was to [...]

Lire la suite

Efficacy and Safety of Cannabidiol Plus Standard Care vs Standard Care Alone for the Treatment of Emotional Exhaustion and Burnout Among Frontline Health CareWorkers During the COVID-19 Pandemic. A Randomized Clinical Trial, José Alexandre S. Crippa et al, 2021,

Efficacy and Safety of Cannabidiol Plus Standard Care vs Standard Care Alone for the Treatment of Emotional Exhaustion and Burnout Among Frontline Health CareWorkers During the COVID-19 Pandemic. A Randomized Clinical Trial José Alexandre S. Crippa, PhD; AntonioW. Zuardi, PhD; Francisco S. Guimarães, PhD; Alline Cristina Campos, PhD; Flávia de Lima Osório, PhD; Sonia Regina Loureiro, PhD; Rafael G. dos Santos, PhD; José Diogo S. Souza, MD; Juliana Mayumi Ushirohira, MD, MSc; Julia Cozar Pacheco, RPh; Rafael Rinaldi Ferreira, PhD, RPh; Karla Cristinne Mancini Costa, MSc; Davi Silveira Scomparin, MSc; Franciele Franco Scarante, MSc; Isabela Pires-Dos-Santos, VMD; Raphael Mechoulam, PhD; Flávio Kapczinski, PhD; Benedito [...]

Lire la suite

Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder. A Randomized Clinical Trial, Alan K. Davis et al., 2020

Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder. A Randomized Clinical Trial Alan K. Davis, PhD; Frederick S. Barrett, PhD; Darrick G. May, MD; Mary P. Cosimano, MSW; Nathan D. Sepeda, BS; Matthew W. Johnson, PhD; Patrick H. Finan, PhD; Roland R. Griffiths, PhD JAMA Psychiatry, 2020, E1-E9. doi : 10.1001/jamapsychiatry.2020.3285   IMPORTANCE : Major depressive disorder (MDD) is a substantial public health burden, but current treatments have limited effectiveness and adherence. Recent evidence suggests that 1 or 2 administrations of psilocybin with psychological support produces antidepressant effects in patients with cancer and in those with treatment-resistant depression. OBJECTIVE : To investigate the effect of psilocybin [...]

Lire la suite

Cannabidiol for the treatment of cannabis use disorder : a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial, Tom P. Freeman et al., 2020

Cannabidiol for the treatment of cannabis use disorder : a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial Tom P Freeman, Chandni Hindocha, Gianluca Baio, Natacha D C Shaban, Emily M Thomas, Danica Astbury, Abigail M Freeman, Rachel Lees, Sam Craft, Paul D Morrison, Michael A P Bloomfield, Dominic O'Ryan, Jane Kinghorn, Celia J A Morgan, Ali Mofeez, H Valerie Curran The Lancet Psychiatry, 2020, doi : 10.1016/S2215-0366(20)30290-X  Abstract Background : A substantial and unmet clinical need exists for pharmacological treatment of cannabis use disorders. Cannabidiol could offer a novel treatment, but it is unclear which doses might be efficacious or safe. Therefore, we aimed to identify efficacious doses and eliminate inefficacious doses in a phase 2a trial using [...]

Lire la suite